We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Just a few weeks out from ASCO, and with more than a touch of inevitability, Roche is axing its IDO/TDO inhibitor work “in its entirety” with partner NewLink Genetics as the fallout from a string of weak IDO trials across biopharma continues.